In August 2013, a federal judge preliminarily approved a $23 million settlement to a class-action lawsuit filed against Merck Sharp & Dohme Corp. for allegedly falsely advertising that Vioxx had greater benefits than the generic versions when these benefits had not been established. According to the settlement terms, class members may receive a cash award of up to $75 with proof of purchase. For more information, go to (In re: Vioxx Products Liability Litigation, MDL No. 1657, E. D. LA.).


Print Friendly, PDF & Email

Tags: ,

Leave a Reply

Back to Top ↑
  • Search Class-Action Tracker

  • Recent Class Actions

  • The Class-Action Tracker is intended to notify consumers about false advertising class-action lawsuits filed around the country, but does not necessarily reflect’s opinion with respect to the lawsuits or disposition of the cases

  • Sign Up for E-mail Updates